Next report date
Report period
Q1 2024
EPS estimate
0.00CHF
Revenue estimate
61.73 MCHF
−0.013CHF
−9.07 MCHF
210.86 MCHF
661.82 M
About PHARMING GROUP
Sector
CEO
Sijmen de Vries
Headquarters
Leiden
Website
Founded
1988
ISIN
NL0010391025
FIGI
BBG00LVF3SR1
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PHGN is 1.118 CHF — it has decreased by 9.98% in the past 24 hours. Watch PHARMING GROUP NV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange PHARMING GROUP NV stocks are traded under the ticker PHGN.
PHARMING GROUP NV is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
PHGN stock is 11.09% volatile and has beta coefficient of 0.77. Track PHARMING GROUP NV stock price on the chart and check out the list of the most volatile stocks — is PHARMING GROUP NV there?
PHGN earnings for the last quarter are 0.00 CHF per share, whereas the estimation was −0.01 CHF resulting in a 103.85% surprise. The estimated earnings for the next quarter are 0.00 CHF per share. See more details about PHARMING GROUP NV earnings.
PHARMING GROUP NV revenue for the last quarter amounts to 61.06 M CHF despite the estimated figure of 56.46 M CHF. In the next quarter revenue is expected to reach 60.47 M CHF.
Yes, you can track PHARMING GROUP NV financials in yearly and quarterly reports right on TradingView.
PHGN stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in PHARMING GROUP NV price.
PHGN net income for the last quarter is −2.33 M CHF, while the quarter before that showed 3.08 M CHF of net income which accounts for −175.71% change. Track more PHARMING GROUP NV financial stats to get the full picture.
Today PHARMING GROUP NV has the market capitalization of 591.26 M, it has decreased by 10.16% over the last week.
No, PHGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PHGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMING GROUP NV stock right from TradingView charts — choose your broker and connect to your account.
PHGN reached its all-time high on Mar 29, 2023 with the price of 1.242 CHF, and its all-time low was 1.104 CHF and was reached on Aug 26, 2022. View more price dynamics on PHGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
We've gathered analysts' opinions on PHARMING GROUP NV future price: according to them, PHGN price has a max estimate of 3.65 CHF and a min estimate of 1.49 CHF. Watch PHGN chart and read a more detailed PHARMING GROUP NV stock forecast: see what analysts think of PHARMING GROUP NV and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMING GROUP NV EBITDA is −10.94 M CHF, and current EBITDA margin is −4.49%. See more stats in PHARMING GROUP NV financial statements.